Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351143 | 1.00 | DRD1 (1.00) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL6953 | 1.00 | DRD1 (1.00) | DRD1CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL29821183 | 0.98 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| Ammonia Solution, Strong SCHEMBL19127610 | 0.98 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL28990395 | 0.98 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| SCHEMBL25373924 | 0.98 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| SCHEMBL17743663 | 0.98 | DRD1 (0.97) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL15209802 | 0.98 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| SCHEMBL38656170 | 0.98 | DRD1 (0.97) | DRD1CYP3A4TDP1 | |
| Phosphine SCHEMBL28527853 | 0.98 | DRD1 (0.97) | DRD1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008798-A1 | PALLADIUM CATALYZED SYNTHESIS OF AMINOALDEHYDE INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-08 | — | — | US | claimed |
| WO-2025122555-A1 | S1P 1 RECEPTOR AGONISTS AND USES THEREOF | VALO HEALTH, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| CN-119528886-A | Shearing inhibitor for pre-miR-21 post-transcriptional processing and preparation method and application thereof | 广东工业大学 | 2025-02-28 | — | — | CN | claimed |
| EP-4188551-B1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-12-18 | — | — | EP | claimed |
| EP-4441043-A1 | SOLID STATE FORMS OF DEUCRAVACITINIB, DEUCRAVACITINIB HCL AND PROCESS FOR PREPARATION OF DEUCRAVACITINIB AND INTERMEDIATES | Teva Czech Industries s.r.o (CZ) | 2024-10-09 | — | — | EP | claimed |
| CN-118666745-A | Preparation method of C2-site arylation or alkenylation quinoline compound | 郑州大学 | 2024-09-20 | — | — | CN | claimed |
| CN-118125926-A | Dimethylaminoethoxy ethanol methyl synthesis process and system | 安徽恒光聚氨酯材料有限公司 | 2024-06-04 | — | — | CN | claimed |
| EP-4359401-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117917412-A | Process for preparing chiral lactones | 帝斯曼知识产权资产管理有限公司 | 2024-04-23 | — | — | CN | claimed |
| WO-2024069646-A1 | IMPROVED PROCESS FOR THE PREPARATION OF RISDIPLAM AND ITS INTERMEDIATES | NATCO PHARMA LIMITED (IN) | 2024-04-04 | — | — | WO | claimed |
| EP-3383838-B1 | PROCESS FOR THE CATALYTIC REVERSIBLE UNSATURATED HYDROCARBON-NITRILE INTERCONVERSION | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-10-25 | — | — | EP | claimed |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | THE BROAD INSTITUTE, INC. | 2023-10-12 | — | — | US | claimed |
| CN-112321526-B | Method for synthesizing heteroaromatic methylamine compound through redox-decarboxylation coupling reaction | 西北师范大学 | 2023-09-22 | — | — | CN | claimed |
| CN-116802187-A | Organometallic compounds | 优米科尔股份公司及两合公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116724021-A | Synthesis of polyfluorinated aryl and heteroaryl carboxamides | 巴斯夫欧洲公司 | 2023-09-08 | — | — | CN | claimed |
| WO-2023102085-A1 | SOLID STATE FORMS OF DEUCRAVACITINIB, DEUCRAVACITINIB HCL AND PROCESS FOR PREPARATION OF DEUCRAVACITINIB AND INTERMEDIATES | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2023-06-08 | — | — | WO | claimed |
| EP-4188551-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | claimed |
| EP-4132902-A1 | PD-CATALYZED AMINATION OF FLUORINATED ARYL CHLORIDES | BASF SE (DE) | 2023-02-15 | — | — | EP | claimed |
| WO-2022271801-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | claimed |
| CN-115322176-A | 2, 3-dihydrobenzofuranyl substituted 1H-indazole compound and preparation and application thereof | 温州医科大学 | 2022-11-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008798-A1 | PALLADIUM CATALYZED SYNTHESIS OF AMINOALDEHYDE INTERMEDIATES | ADH1C, AOC1, AOC2 | DRD1 266/4885CYP3A4 3031/4885TDP1 332/4885 |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | PNPO, THPO, PAH | DRD1 4470/4885CYP3A4 41/4885TDP1 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.